Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Schering-Plough announces quarterly dividends

Schering-Plough announces quarterly dividends

15th December 2008

Schering-Plough’s board of directors has declared the company’s quarterly dividend.

Announced as $0.065 (0.043 pounds) per common share, the amount will be paid on February 27th next year to shareholders of record as of February 6th.

The organisation’s preferred stock has also been declared as $3.75 per share on the company’s 2007 Mandatory Convertible Preferred stock – with payment due on February 16th and recording from February 2nd.

Earlier this month, Schering-Plough said it had received approval for its Temodal (temozolomide) intravenous formulation from the European Medicines Agency Committee for Medicinal Products for Human Use.

The capsules are a chemotherapy agent for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and monotherapy – and can also be used for malignant gliomas, such as anaplastic astrocytoma.

Speaking at the time, Robert Spiegel, chief medical officer and senior vice-president at Schering Plough Research Institute, said: “Temodal is a well recognised, effective treatment for patients in Europe with malignant gliomas, but is only available orally.”

Based in Kenilworth, US, Schering-Plough employs 55,000 people around the world and had net sales in 2007 of $12.7 billion.

The company has business operations in more than 140 countries.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.